Literature DB >> 1679280

Immune system-associated antigens on the surface of peripheral blood lymphocytes in patients with Alzheimer's disease.

T Ikeda1, K Yamamoto, K Takahashi, M Yamada.   

Abstract

We investigated the immune-associated antigens of peripheral lymphocytes from 13 patients with Alzheimer's disease (AD) and 13 age-matched healthy control subjects using two-color analysis with flow cytometry. Four ratios of immune-related antigens, T/B lymphocytes, CD4/CD8, CD4/CD45R and CD4/HLA-DR, were compared for the AD and control groups. The T/B and CD4/CD8 ratios did not differ between the groups, the ratio of CD4+CD45R+ subset in the AD group was lower than the ratio in the control group, and the ratios of CD4+ CD45R- and CD4+HLA-DR+ subsets in the AD group were significantly higher. Further, in the AD group, the CD4+ CD45R+/CD4+ ratio was lower and the CD4+ CD45R- CD4+ ratio was higher than in the control group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679280     DOI: 10.1111/j.1600-0447.1991.tb05573.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

1.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

3.  Immunophenotypes in the circulation of patients with mild cognitive impairment.

Authors:  Shino Magaki; Steven M Yellon; Claudius Mueller; Wolff M Kirsch
Journal:  J Psychiatr Res       Date:  2007-02-23       Impact factor: 4.791

Review 4.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

5.  IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology.

Authors:  Isabelle St-Amour; Isabelle Paré; Cyntia Tremblay; Katherine Coulombe; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2014-03-22       Impact factor: 8.322

6.  Enhanced susceptibility of triple transgenic Alzheimer's disease (3xTg-AD) mice to acute infection.

Authors:  Rebecca Montacute; Kerry Foley; Ruth Forman; Kathryn Jane Else; Sheena Margaret Cruickshank; Stuart McRae Allan
Journal:  J Neuroinflammation       Date:  2017-03-11       Impact factor: 8.322

7.  Application of Artificial Intelligence Modeling Technology Based on Fluid Biopsy to Diagnose Alzheimer's Disease.

Authors:  Yuan Sh; Benliang Liu; Jianhu Zhang; Ying Zhou; Zhiyuan Hu; Xiuli Zhang
Journal:  Front Aging Neurosci       Date:  2021-12-03       Impact factor: 5.750

8.  Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis.

Authors:  Le-Tian Huang; Cheng-Pu Zhang; Yi-Bing Wang; Jia-He Wang
Journal:  Front Aging Neurosci       Date:  2022-05-06       Impact factor: 5.750

Review 9.  Inflammaging as a prodrome to Alzheimer's disease.

Authors:  Brian Giunta; Francisco Fernandez; William V Nikolic; Demian Obregon; Elona Rrapo; Terrence Town; Jun Tan
Journal:  J Neuroinflammation       Date:  2008-11-11       Impact factor: 8.322

10.  Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study.

Authors:  Jay Amin; Delphine Boche; Zoe Clough; Jessica Teeling; Anthony Williams; Yifang Gao; Lindsey Chudley; Laurie Lau; Florence Smith; Scott Harris; Clive Holmes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-09-23       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.